Compare TECH & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TECH | SNN |
|---|---|---|
| Founded | 1976 | 1856 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4B | 12.3B |
| IPO Year | 1995 | 2002 |
| Metric | TECH | SNN |
|---|---|---|
| Price | $72.68 | $30.18 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 13 | 6 |
| Target Price | ★ $70.50 | $32.32 |
| AVG Volume (30 Days) | ★ 2.7M | 1.2M |
| Earning Date | 11-17-2026 | 08-04-2026 |
| Dividend Yield | 0.44% | ★ 2.53% |
| EPS Growth | ★ 152.17 | N/A |
| EPS | ★ 1.16 | N/A |
| Revenue | ★ $1,215,039,000.00 | N/A |
| Revenue This Year | $4.38 | $4.75 |
| Revenue Next Year | $10.06 | $5.15 |
| P/E Ratio | ★ $62.65 | $64.97 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $43.20 | $26.30 |
| 52 Week High | $72.75 | $37.09 |
| Indicator | TECH | SNN |
|---|---|---|
| Relative Strength Index (RSI) | 57.86 | 61.82 |
| Support Level | $72.11 | $29.18 |
| Resistance Level | $72.75 | $30.52 |
| Average True Range (ATR) | 0.11 | 0.47 |
| MACD | -0.00 | 0.08 |
| Stochastic Oscillator | 80.00 | 62.64 |
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 40% of the UK-based firm's revenue comes from orthopedic products, and another 31% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the US, just over 30% is from other developed markets, and emerging markets account for the remainder.